Short answer
Taysha Gene Therapies, Inc. (TSHA) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 84.86% shareholder participation, with 243,857,812 of 287,341,999 shares represented.
Taysha Gene Therapies, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 84.86% shareholder participation, with 243,857,812 of 287,341,999 shares represented
- Sean P. Nolan and Laura Sepp-Lorenzino elected directors through 2029
- Deloitte & Touche ratified as 2026 auditor with 243,814,085 votes for and 25,551 against
- Executive compensation approved advisory basis, with 168,142,551 votes for and 36,396,784 against
- Annual advisory votes on executive compensation selected by 203,825,717 votes, and adopted by the Board
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Taysha Gene Therapies, Inc. 8-K filings
Get the next TSHA 8-K as it lands
Follow TSHA for push alerts, or ask the research agent what this filing means.